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Introduction
The neuronal insulating layer, myelin, is fragmented after a spi-
nal lesion, releasing the extrinsic inhibitory molecules myelin-
associated  glycoprotein  (MAG),  Nogo,  and  oligodendrocyte 
myelin glycoprotein (He and Koprivica, 2004) that inhibit axo-
nal outgrowth and functional recovery after injury. These myelin 
proteins signal through the neuronal membrane–bound Nogo 
receptor (NgR) complex, which includes NgR1 (Chen et al., 
2000; GrandPré et al., 2000), Lingo-1 (Mi et al., 2004), and 
p75
NTR (Domeniconi et al., 2002; Wong et al., 2002) or TROY 
(Park et al., 2005). Myelin protein engagement of the NgR com-
plex activates RhoA, which induces Rho kinase–dependent phos-
phorylation of cofilin and, thus, actin depolymerization and 
growth cone collapse (He and Koprivica, 2004).
The NgR complex (Bregman et al., 1995; Thallmair   
et al., 1998; GrandPré et al., 2000; Merkler et al., 2001; Li and 
Strittmatter, 2003; Mi et al., 2004) is vital for growth cone col-
lapse and inhibition of neurite outgrowth. Although both the 
up- and downstream components of NgR complex–dependent 
signaling have been extensively studied (He and Koprivica, 
2004), the transcriptional regulation of its individual members 
remains unknown.
The  overexpression  of  the  transcription  factor  retinoic 
acid (RA) receptor 2 (RAR-2) promotes neurite outgrowth in 
primary neurons cultured on inhibitory substrates and induces 
axonal regeneration via neuronal intrinsic pathways in vivo   
after a spinal lesion (Wong et al., 2006; Yip et al., 2006). More 
recently, phosphorylated AKT, a serine/threonine kinase, was 
associated with the beneficial effects of RAR-2 (Agudo et al., 
2010); however, thus far, no direct transcriptional targets for 
RAR-2 that promote neurite outgrowth on inhibitory substrates 
have been identified.
A
fter an acute central nervous system injury, axo-
nal regeneration is limited as the result of a lack 
of neuronal intrinsic competence and the pres-
ence of extrinsic inhibitory signals. The injury fragments 
the myelin neuronal insulating layer, releasing extrinsic 
inhibitory molecules to signal through the neuronal mem-
brane–bound Nogo receptor (NgR) complex. In this paper, 
we show that a neuronal transcriptional pathway can   
interfere with extrinsic inhibitory myelin-dependent signal-
ing, thereby promoting neurite outgrowth. Specifically, ret-
inoic acid (RA), acting through the RA receptor  (RAR-),   
inhibited myelin-activated NgR signaling through the 
transcriptional repression of the NgR complex member 
Lingo-1. We show that suppression of Lingo-1 was re-
quired for RA–RAR- to counteract extrinsic inhibition of 
neurite outgrowth. Furthermore, we confirm in vivo that 
RA treatment after a dorsal column overhemisection injury 
inhibited Lingo-1 expression, specifically through RAR-. 
Our findings identify a novel link between RA–RAR-– 
dependent  proaxonal  outgrowth  and  inhibitory  NgR   
complex–dependent signaling, potentially allowing for the 
development of molecular strategies to enhance axonal 
regeneration after a central nervous system injury.
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RA–RAR- represses the myelin-dependent 
induction of Lingo-1
To investigate whether RA–RAR- is able to affect myelin-
derived inhibitory signals by directly modulating the gene ex-
pression of the NgR complex members, we conducted an in silico 
analysis. We used a specific algorithm developed for transcrip-
tion elements (Transcription Element Search System [TESS]) 
to identify RAREs on the promoters of NgR, Lingo-1, p75
NTR, 
and TROY. This led to the discovery of novel RAREs on both 
the Lingo-1 (a full site) and NgR (only half sites) promoters 
(Fig. 2 A), suggesting that they may be possible RA–RAR- 
target genes. Therefore, we examined the gene expression of 
Lingo-1 and NgR, as well as the other NgR complex members, 
by real-time RT-PCR in wild-type and RAR-
/ CGNs cul-
tured on PDL or myelin, and we discovered that both Lingo-1 
and NgR1 expression was increased in CGNs plated on myelin 
(Fig. 2 B). If RA transcriptionally regulated Lingo-1 and NgR 
expression on myelin via RAR-, the delivery of RA would 
affect their gene expression in wild-type but not in RAR-
/ 
CGNs. Indeed, myelin-induced Lingo-1 expression was re-
pressed by RA in wild-type but not RAR-
/ CGNs at 8 h and 
even further so at 24 h after plating (Fig. 2 C). Myelin also in-
duced a significant increase in Lingo-1 protein expression, which 
was abrogated by RA treatment in wild-type but not RAR-
/ 
CGNs (Fig. 2 D). The expression of NgR1 was not preferen-
tially regulated through RA–RAR-, as its gene expression was 
significantly affected by RA both in wild-type and RAR-
/ 
CGNs (unpublished data). It is important to note that without 
Lingo-1, the NgR complex of NgR, Lingo-1, and p75
NTR or TROY 
is unable to transmit myelin inhibitory signals (Mi et al., 2004; 
Park et al., 2005; Shao et al., 2005; Ji et al., 2006); therefore, 
modest yet significant changes in its expression can have pro-
found effects. Also noteworthy, myelin transcriptional regulation 
of Lingo-1 appears to be independent of RA–RAR- tran-
scriptional regulation of Lingo-1 as observed by the increase in 
Lingo-1 expression in RAR-
/, which is similar to that seen 
in wild-type CGNs. This indicates that the RA–RAR- path-
way is not responsible for Lingo-1 up-regulation by myelin. 
Altogether, these data suggest that Lingo-1 gene expression is 
induced by myelin and that RA–RAR- acts as a repressor of 
the myelin-dependent gene induction of Lingo-1 through the 
possible binding to novel RAREs in its promoter.
RAR- occupies a RARE on Lingo-1, 
repressing its expression
Typically, the nuclear receptor RAR- bound by its ligand 
RA forms a heterodimer with the retinoid X receptor (RXR), 
binds to RAREs in gene promoters, and activates transcription 
(Chambon, 1996). However, there have been several documented 
cases in which RAR- was found to occupy promoters indepen-
dently from RXR and to repress transcription (Glass et al., 
1989; Lipkin et al., 1992; Schoorlemmer et al., 1994).
To specifically explore whether RAR- acts as a repres-
sor of Lingo-1 gene expression, we electroporated both wild-
type and RAR-
/ CGNs cultured on PDL or myelin with 
human RAR-2 in combination with RA or vehicle and mea-
sured Lingo-1 expression by real-time RT-PCR. In wild type, 
Importantly, transcriptional proneurite outgrowth and 
extrinsic inhibitory pathways have not been previously shown 
to directly intersect or form a unique signaling cascade. Here, 
we show that RA-bound RAR- occupies a specific RA re-
sponse element (RARE) on the Lingo-1 promoter, transcrip-
tionally repressing Lingo-1 myelin-dependent gene activation. 
Furthermore, Lingo-1 expression is required for RA–RAR- 
to  counteract  myelin-dependent  inhibition  of  neurite  out-
growth. Finally, we show in vivo that RA treatment after 
a dorsal column overhemisection lesion inhibits Lingo-1 ex-
pression, specifically through RAR-. Our findings identify 
a  novel  pathway  that  specifically  links  the  RA–RAR-– 
dependent proaxonal outgrowth and the inhibitory NgR complex–
dependent signaling.
Results and discussion
RA–RAR- counteracts myelin- 
dependent inhibition
We  wanted  to  examine  the  RAR-–dependent  molecular 
pathways  involved  in  neurite  outgrowth  in  nonpermissive 
conditions after the administration of the clinically available   
all-trans RA, a lipophilic vitamin A derivative that readily 
transverses the blood–brain barrier (Le Doze et al., 2000). 
Cultured mouse cerebellar granular neurons (CGNs) were 
used as an in vitro neurite outgrowth model of the central ner-
vous system (Dubreuil et al., 2003; Yamashita and Tohyama, 
2003; Madura et al., 2004). When CGNs were cultured on 
poly-d-lysine (PDL) or PDL plus myelin substrate (henceforth 
myelin) with 1 µM RA (a dosage known to reach therapeutic 
levels in humans; Miano and Berk, 2000) or vehicle (DMSO) 
administered at the time of plating, we observed that RA pro-
moted neurite outgrowth (approximately twofold) in CGNs on 
a nonpermissive myelin but not on a permissive PDL substrate 
(Fig. 1, A and B). Given that these effects may be influenced 
by cell survival, we examined cell survival between samples 
by the analysis of apoptotic nuclei and found no differences 
(Fig. S1 A). RAR- is expressed in CGNs (Fig. S1 B) and 
may be the RAR relevant for RA-induced neurite outgrowth 
(Corcoran et al., 2002). Therefore, neurite outgrowth exper-
iments  were  performed  in  RAR-
/  CGNs  to  investigate 
whether RAR- is essential to the ability of RA to counteract 
myelin-dependent inhibition of neurite outgrowth. Contrary to 
what we observed in wild-type CGNs, neurite outgrowth was 
no longer enhanced on myelin with RA in RAR-
/ CGNs 
(Fig. 1, A and B).
The activation of RhoA is a classical downstream event in 
myelin-dependent activation of NgR signaling. When we plated 
wild-type CGNs on PDL with or without RA treatment for 24 h, 
at which time we added 1 µg/ml MAG for 15 min, we found that 
the RA-dependent increase in neurite outgrowth is associated 
with a decrease in RhoA activation (Fig. 1 C). It is also impor-
tant to note that RA did not modify neurite outgrowth through 
RAR- when CGNs were plated on another inhibitory sub-
strate, chondroitin sulfate proteoglycans (CSPGs; Fig. S1 C), 
suggesting that RA–RAR- functions by preferentially modu-
lating myelin-dependent signaling.1149 RAR- promotes outgrowth by repressing Lingo-1 • Puttagunta et al.
RARE2. To this end, we performed a ChIP with the RXR   
antibody that showed no change in myelin- or RA-dependent 
Lingo-1 promoter occupancy (Fig. 3 E), suggesting that my-
elin and RA specifically regulate RAR- occupancy of the 
Lingo-1 promoter.
To determine whether RAR- is a repressor of Lingo-1 
transcription, luciferase assays were performed. The proximal 
Lingo-1  genomic  region  of  1,000  bp  containing  both  the 
RARE1 and RARE2 was cloned into a luciferase vector driven 
by a cytomegalovirus promoter (Fig. 3 F). Because of the lim-
ited transfection efficiency of the luciferase vector in primary 
neurons, which strongly restricted the quality of the luciferase 
signal, luciferase assays were performed in neuroblastoma cells   
(previously shown to be responsive to RA and sensitive to   
myelin-dependent inhibition of neurite outgrowth; Caroni et al., 
1988; Schwab and Caroni, 1988; Encinas et al., 1999; Merrill 
et al., 2004) transfected with RAR-2 and plated on PDL or 
myelin. These experiments clearly demonstrate that Lingo-1 lu-
ciferase activity is enhanced by myelin as compared with PDL   
whereas  RA  treatment  alone  repressed  Lingo-1  expression, 
RAR-2 overexpression alone only partially repressed Lingo-1,   
but in combination with RA, it fully attenuated myelin-induced 
Lingo-1 expression (Fig. 3 A). In RAR-
/, RA alone could not 
inhibit Lingo-1, likely as a result of the absence of basal RAR-  
expression; however, exogenous overexpression of RAR-2 
alone inhibited myelin-induced Lingo-1 expression, an effect   
that was enhanced with additional RA treatment (Fig. 3 B). Sub-
sequent  chromatin  immunoprecipitation  (ChIP)  experiments 
demonstrated that RAR- specifically occupies the Lingo-1 
in silico–predicted RARE1, but not the RARE2 (Fig. 3 C), in a 
chromatin environment (Fig. 3 D). Interestingly, Lingo-1 pro-
moter occupancy was strongly enhanced by RA when CGNs 
were plated on myelin, whereas myelin itself reduced RAR- 
occupancy in comparison with neurons on PDL (Fig. 3 D). As 
RAR- occupies RAREs as a homodimer or as a heterodimer 
with RXR (Chambon, 1996; Vernet et al., 2006), we sought to de-
termine whether RXR also underwent myelin- or RA-dependent 
changes in Lingo-1 promoter occupancy on the RARE1 or   
Figure 1.  RA–RAR- counteracts myelin-dependent inhibition of neurite outgrowth through RhoA inhibition. (A) Wild-type and RAR-
/ CGNs cultured 
on PDL or myelin with vehicle or 1 µM RA for 24 h. Bar, 50 µm. (B) Quantification of neurite length. Myelin inhibition of neurite outgrowth was significantly 
counteracted in wild type, but not RAR-
/, by RA. (C) Wild-type CGNs were stressed with MAG for 15 min. Strong induction of RhoA activation with 
MAG was significantly inhibited by prior 24-h RA treatment (n = 3). **, P < 0.01; ***, P < 0.001. Data are plotted as the mean ± SEM.JCB • VOLUME 193 • NUMBER 7 • 2011   1150
1,000-bp fragment but not within the RARE1, as myelin induced 
luciferase expression of both the Lingo-1 promoter and the mu-
tant Lingo-1 promoter.
Together, we show for the first time that myelin strongly 
inhibits the recruitment of RAR- to the RARE1 in the Lingo-1 
promoter and that RA treatment allows RAR- to occupy the 
and repressed by the administration of the ligand RA (Fig. 3 G). 
Furthermore, when the RARE1 that was shown to specifically 
bind RAR- via a ChIP assay was mutated, there was no RA-
dependent repression observed in luciferase activity on my-
elin (Fig. 3 G). These data also suggest that myelin-dependent   
induction of Lingo-1 expression must take effect within this 
Figure  2.  RA–RAR-  represses  the  myelin-
dependent induction of Lingo-1. (A) A diagram 
of newly discovered RAREs in the Lingo-1 and 
NgR promoters. (B) Gene expression analysis 
of the NgR complex members from wild-type 
and  RAR-
/  CGNs  on  PDL  and  myelin.   
(C) Lingo-1 myelin-dependent gene expression 
is repressed by RA treatment in wild type but 
not RAR-
/ for 8 and 24 h. (D) Protein ex-
pression analysis and representative immuno-
blot of Lingo-1 from CGNs. Myelin induced a 
significant increase in Lingo-1 protein expres-
sion, which was attenuated by 24-h RA treat-
ment in wild type but not RAR-
/ (n = 3). 
One-way ANOVA Bonferroni posttests: *, P < 
0.05; **, P < 0.01; ***, P < 0.001. Data are 
plotted as the mean ± SEM.1151 RAR- promotes outgrowth by repressing Lingo-1 • Puttagunta et al.
RXR, it will be of great interest to further determine the RAR- 
binding partners, possibly histone deacetylases, involved in Lingo-1 
repression on myelin.
RARE1 of the Lingo-1 promoter, thereby inhibiting its expression 
in response to myelin. Given this atypical function for RAR- 
in transcriptional repression, without its classical binding partner 
Figure 3.  RAR- occupies a novel RARE on the Lingo-1 promoter and represses Lingo-1 expression. (A) Real-time RT-PCR gene expression analysis of 
Lingo-1 in wild-type CGNs transfected with RAR-2 plated on myelin versus PDL with vehicle or RA. RA represses Lingo-1 gene expression with a similar 
pattern to that observed with both RA and RAR-2, whereas RAR-2 alone has a more modest repression. (B) Real-time RT-PCR gene expression analysis of 
Lingo-1 in RAR-
/ CGNs transfected with RAR-2 plated on myelin versus PDL revealed a rescue of Lingo-1 inhibition and was further inhibited in com-
bination with RA. (A and B) The dashed lines represent the level of no change (onefold). (C) A diagram of two newly discovered RAREs (bold letters) in the 
Lingo-1 promoter. Small arrows indicate primer sets used for ChIP assays. (D) A ChIP assay shows a significant decrease in the occupancy of the Lingo-1 
RARE1 by RAR- on myelin in comparison with PDL in wild-type (WT) CGNs and a significant increase in occupancy with RA on myelin versus myelin with 
vehicle. (E) A ChIP assay shows no significant change in the occupancy of either the Lingo-1 RAREs by RXR on myelin in comparison with PDL or with RA 
treatment on myelin in wild-type CGNs. Unpaired two-tailed t test: *, P < 0.05; ***, P < 0.001. (F) A diagram of the Lingo-1 luciferase construct. CMV, 
cytomegalovirus. (G) Transfection of SH-SY5Y cells with RAR-2 in combination with the Lingo-1 promoter or mutant Lingo-1 promoter luciferase expres-
sion plasmid with or without RA (24 h) revealed an increase in both luciferase expression plasmids on myelin versus PDL, but only the Lingo-1 promoter 
luciferase expression plasmid was attenuated by RA treatment (n = 3). RLU, relative light unit. One-way ANOVA Bonferroni posttests: *, P < 0.05; ***,   
P < 0.001. Data are plotted as the mean ± SEM.JCB • VOLUME 193 • NUMBER 7 • 2011   1152
et al., 2003; Fournier et al., 2003; Mi et al., 2004). Interestingly, 
the administration of RA not only activates the transcription 
factor RAR- but also increases its gene expression (Fig. S1 B; 
Sucov et al., 1990). What remains to be determined is whether 
RA will repress Lingo-1 expression after SCI, as this would 
have  relevant  implications  for  the  described  proregenerative 
role of RA–RAR- pathways. Furthermore, it would provide 
physiological validation of the novel molecular link we have de-
scribed here in vitro. Indeed, observations from an in vivo study 
in rats 14 d after SCI (Mi et al., 2004) and our own in vitro work 
that myelin induces Lingo-1 expression suggest that Lingo-1 
expression would be increased in vivo in mice after SCI. How-
ever, we did not observe such an increase (Fig. 5, A and B), 
likely because of the already high basal level of Lingo-1 in the 
spinal cord. This result is also consistent with another study that 
shows no change in Lingo-1 expression in mice hours to days 
after SCI in supraspinal neurons (Barrette et al., 2007). More 
importantly, we show that Lingo-1 expression is repressed by 
RA treatment (5 mg/kg daily via intraperitoneal [IP] injection) 
versus vehicle (DMSO) after a dorsal overhemisection (Fig. 5, 
A and B). Underlining the importance of Lingo-1 repression 
is the fact that the presence of all three members of the NgR 
complex is necessary for RhoA activation (Mi et al., 2004; Park 
et al., 2005; Shao et al., 2005; Ji et al., 2006). Moreover, Lingo-1 
repression is not observed in RAR-
/ mice. These in vivo 
data  provide  physiological  relevance  to  the  novel  molecular 
mechanism we have elucidated in vitro.
Our findings identify for the first time a direct link be-
tween the neuronal proneurite outgrowth RA–RAR- pathway 
RA–RAR- protects from myelin-dependent 
inhibition by inhibiting Lingo-1
To  ascertain  whether  the  RA–RAR-  pathway  counteracts 
myelin-dependent inhibition of neurite outgrowth selectively 
through Lingo-1, we overexpressed mouse Lingo-1 in CGNs 
cultured on myelin to rescue RA-induced Lingo-1 inhibition. 
These experiments were performed in CGNs treated with RA 
or vehicle for 24 h; thereafter, neurite length was measured. We 
observed that the overexpression of Lingo-1 on PDL did not 
affect neurite outgrowth (Fig. 4 A), as neurite lengths were not 
significantly different between control and Lingo-1–transfected 
neurons (not depicted). However, Lingo-1 overexpression on 
myelin (Fig. 4 B) is sufficient to fully abolish RA-dependent 
inhibition of neurite outgrowth in wild type but did not sub-
stantially affect neurite outgrowth in the absence of RA (Fig. 4,   
B and C; and Fig. S2). Furthermore, Lingo-1 gene silencing 
experiments, which repressed Lingo-1 expression at both the 
mRNA and protein level (Fig. S3, A and B), enhanced neurite 
outgrowth similar to that of RA treatment alone (Fig. 4 D). 
These data confirm that the protective role of RA–RAR- in 
neurite outgrowth on an inhibitory myelin substrate involves 
Lingo-1 inhibition.
RA–RAR- inhibits Lingo-1 expression in vivo  
after a dorsal overhemisection lesion
It has been established that the inhibition of Lingo-1 or RhoA 
activation, as well as the overexpression of RAR-2 or the ad-
ministration of an RAR- agonist, promotes axonal sprouting 
and functional recovery after spinal cord injury (SCI; Dubreuil 
Figure  4.  Lingo-1  overexpression  inhibits 
RA-dependent antagonism of myelin-mediated 
inhibition  of  neurite  outgrowth,  and  Lingo-1 
silencing induces neurite outgrowth on myelin. 
(A) Immunocytochemistry of cultured wild-type 
CGN on PDL after electroporation with Lingo-1 
shows lack of inhibitory effects. Bar, 20 µm. 
(B) Immunocytochemistry of wild-type CGN on 
myelin after electroporation (24 h) with GFP–
Lingo-1 or GFP–empty vector (EV). Bar, 20 µm.   
(C) On myelin, control but not Lingo-1 electro-
porated  wild-type  CGN  with  RA  treatment   
(24 h) counteracted myelin-induced inhibition 
of neurite outgrowth (in triplicate, 60–70 cells/
group).  One-way  ANOVA  Bonferroni  post-
tests: ***, P < 0.001. (D) Wild-type CGNs 
were cultured on PDL or myelin after coelec-
troporation with either scrambled siRNA/GFP 
or siLingo-1/GFP for 24 h for quantification 
of neurite length. Myelin inhibition of neurite 
outgrowth  was  significantly  counteracted  in 
siLingo-1/GFP but not scrambled siRNA (scr-
siRNA)/GFP.  Neurite  length  analysis  was 
performed  in  triplicate  (100  cells/group). 
One-way ANOVA Bonferroni posttests: *, P < 
0.05; ***, P < 0.001. Data are plotted as the 
mean ± SEM.1153 RAR- promotes outgrowth by repressing Lingo-1 • Puttagunta et al.
outgrowth (Fig. 5 C). This is the first report of transcriptional 
regulation of an NgR complex member, suggesting that tran-
scriptional control plays a critical functional role for at least one 
NgR complex member, Lingo-1. Furthermore, we demonstrate 
and extrinsic inhibitory NgR complex–dependent signaling. We 
show that RA-bound RAR- occupies a novel RARE on the 
Lingo-1 promoter, transcriptionally repressing Lingo-1 gene 
activation and thus RhoA activation, culminating in neurite 
Figure 5.  In vivo RA–RAR- inhibits Lingo-1 expression after SCI. (A) A laminectomy (Sham) or T8 dorsal overhemisection lesion was performed on either 
wild-type or RAR-
/ mice (n = 3 per group) with vehicle (DMSO) or 5 mg/kg RA daily IP injections after injury (SCI control or SCI RA). dpo, days post 
operation. (B) Representative immunoblot analysis of the SCI site showed that RA significantly repressed Lingo-1 expression in wild-type but not RAR-
/ 
mice (n = 3 per group). One-way ANOVA Bonferroni posttests: **, P < 0.01. All data are plotted as the mean ± SEM. (C) A comprehensive diagram of 
the results presented in this paper shows the role of RA–RAR- in transcriptionally repressing the NgR signaling pathway, thus leading to neurite outgrowth. 
RAR- occupies a novel RARE on the Lingo-1 promoter, thereby repressing Lingo-1 expression. This leads to a decrease in myelin-dependent RhoA activation 
and neurite outgrowth. OMgp, oligodendrocyte myelin glycoprotein; ROCK, Rho kinase.JCB • VOLUME 193 • NUMBER 7 • 2011   1154
two predesigned siRNAs (20 nM) were used (Silencer select IDs 108134 
and 108133; Invitrogen). Scrambled siRNAs were used as a control. The 
efficiency of gene silencing was assessed by real-time RT-PCR and Western 
analysis after electroporation.
In silico transcription factor binding site analysis
A  region  of  2,000  bp  of  the  5  untranslated  region  of  the  Lingo-1,   
NogoR1, p75
NTR, and TROY genes was analyzed using TESS, a search en-
gine which can identify binding sites using site or consensus strings and po-
sitional weight matrices from the TRANSFAC database, JASPAR database, 
Information Matrix Database, and Computational Biology and Informatics 
Laboratory–GibbsMat database.
ChIP assay
ChIP assays were performed according to the manufacturer’s recommen-
dation (17–295; Millipore). In brief, 24 × 10
7 CGNs were grown in the 
absence or presence of 1 µM RA for 24 h either on PDL or myelin and 
were subsequently fixed with 1% formaldehyde for 10 min at 37°C. After 
cell lysis (0.5% SDS, 100 mM NaCl, 50 mM Tris-HCl, pH 8.0, and 5 mM 
EDTA), extracts were sonicated to shear DNA to lengths of 200–600 bp.   
Chromatin solutions were incubated overnight with agitation with 8–10 µg 
of rabbit polyclonal RAR- (C-19) X sc-552 (Santa Cruz Biotechnology, 
Inc.) or rabbit polyclonal RXR (N 197) X sc-774 (Santa Cruz Biotech-
nology, Inc.). The following day, protein A/G–agarose beads, blocked 
with salmon sperm DNA, were added to each reaction to precipitate 
antibody complexes. The precipitated complexes were washed and then 
incubated for 4 h at 65°C in parallel with input samples to reverse the 
cross-link. DNA was isolated by phenol/chloroform extraction followed 
by ethanol precipitation in the presence of sodium acetate. Input, IP, and 
no-antibody fractions were then analyzed by quantitative PCR (ABI 7000; 
Applied Biosystems) with appropriate primer pairs for RAREs. The prim-
ers used were as follows: Lingo-1 RARE1 forward 5-CAAGCGGCTCTT-
GACCTTAG-3 and reverse 5-CAAACAGACCCTTCCAGAGG-3 (201 
bp) and Lingo-1 RARE2 forward 5-GCCAGAGTCCTGAAGAGGTG-3 
and reverse 5-GCACCCTCCTGTCTGAACAT-3 (163 bp). For real-time 
quantitation of PCR products and fold change measurements after ChIP, 
each experimental sample was normalized to input and no-antibody frac-
tions and was presented as the fold change between individual experi-
mental conditions throughout our results. Three independent experiments 
in triplicate were evaluated for each condition, and the Ct method 
was used for exact fold change assessment as we have previously re-
ported (Tedeschi et al., 2009b).
Luciferase assay
An 1,000-bp region of the Lingo-1 proximal promoter containing the 
RARE1 and RARE2 or a RARE1 mutated sequence was cloned by PCR from 
genomic DNA of mouse CGNs and ligated into the HindIII and XhoI restric-
tion sites of a luciferase reporter (plasmid 17870; Addgene) for trans-
fection and luciferase experiments. The primers used to clone a 1,000-bp 
region of the Lingo-1 proximal promoter containing the RARE1 and RARE2 
were  forward  5-CCCAAGCTTTGGCTGGCAGCCCCAGCCTC-3  and 
reverse  5-CCGCTCGAGTGCCTTAGGATCCCTAGAAA-3.  An  expres-
sion plasmid with a mutated RARE1 sequence was also created by site-
directed  mutagenesis  of  this  newly  cloned  luciferase  construct  (Agilent 
Technologies). The two overlapping primers carrying seven mutations 
that were designed using the Stratagene primer design program were 
sense 5-CCCAAGTTTGGCTGGCAGCCCCAGCCTCTGAGGTCATCTA-
TGCCAGCCCTGGCGGAAAGGGAGTGAGTCAGGTGTGGAT-3 and 
antisense  5-CCGCTCGAGTGCCTTAGGATCCCTAGAAAAGAGGAGA-
AACAGGGGAGATCTGTAGGGGTCCATGAGGGACAGAGGGGCTG-3.   
Constructs were sequenced to verify the cloned sequences. The mutant 
sequence within the RARE region that was generated was 5-AGTTCA-
CAAAGGCTG-3,  versus  the  wild-type  RARE  corresponding  domain 
5-GACCCACAAAGGGGT-3. These constructs were then used for trans-
fection experiments. In brief, SH-SY5Y cells were seeded at 350,000 cells 
per well in a 24-well plate with DME plus 10% FBS, 100 U/ml penicil-
lin, and 100 mg/ml streptomycin 3 h before transfection. Lipofectamine 
reagent/total DNA ratios were according to standard recommendation, 
with each well receiving 380 ng Lingo-1Prom-Luc reporter, 380 ng human   
RAR-2 plasmid, 20 ng pRL-TK-Renilla-luciferase (Promega), and 20 ng 
EGFP plasmid (Lonza) for a total of 800 ng of total DNA. Upon transfec-
tion, some wells were stimulated with 1 µM RA (Sigma-Aldrich) for 24 h. 
After a 24-h incubation, cells were harvested and lysed with 100 µl of 
passive lysis buffer, and luciferase activities were determined using the Dual-
Luciferase kit (Promega).
that Lingo-1 expression is required for RA–RAR- to counter-
act myelin-dependent inhibition of neurite outgrowth. Finally, 
we provide physiological confirmation that RA represses Lingo-1 
expression in vivo after SCI in an RAR-–dependent manner. 
These findings are consistent with, yet further develop, earlier 
studies that showed a role for RAR-2 in promoting axonal re-
generation after SCI (Corcoran et al., 2002; Wong et al., 2006; 
Yip et al., 2006). Given that RA and the regenerative molecule 
cyclic AMP (Qiu et al., 2002) induce expression of RAR-  
(Sucov et al., 1990; Kruyt et al., 1992), it will be of interest 
to determine their combined regenerative effect. Understanding 
the precise molecular mechanism involved in induction of neu-
ronal regeneration by RA–RAR- signaling may allow for more 
comprehensive combinatorial therapies with clinically available 
RA, for example with the CSPG inhibitor chondroitinase ABC 
(chondroitin A, B, and C lyase), for the treatment of SCI.
Materials and methods
Cell culture
CGNs were prepared from the cerebella of 8-d-old wild-type or RAR-
/ 
(NE75 RAR-
L/L; Chapellier et al., 2002) mice after standard proce-
dures. In brief, the cerebella were collected and incubated for 15 min at 
37°C in an ionic medium with 0.025% trypsin and 0.05% DNase I (Sigma-
Aldrich). 0.04% trypsin inhibitor (Sigma-Aldrich) was added to the tissue 
and collected by centrifugation. The subsequent pellet was triturated, cen-
trifuged, resuspended in basal Eagle’s medium (Invitrogen), and supple-
mented  with  10%  bovine  calf  serum  (Invitrogen),  25  mM  KCl,  4  mM 
glutamine, and 100 ng/ml gentamycin. These disassociated CGNs were 
plated on either PDL or myelin with 1 µM RA (Sigma-Aldrich) or vehicle 
(DMSO) for 24 h in a humidified atmosphere of 5% CO2 in air at 37°C. 
The SH-SY5Y neuroblastoma cell line was grown in DME supplemented 
with 10% FBS (Invitrogen), 100 U/ml penicillin, and 100 mg/ml strepto-
mycin (Invitrogen) in a humidified atmosphere of 5% CO2 in air at 37°C.
Neurite length analysis
Immunofluorescence (DAPI, FITC, and Texas red) was detected using a   
microscope (Axiovert 200M; Carl Zeiss), and pictures were taken at 10× 
(0.30 NA; Carl Zeiss) or 20× (LD Achroplan, 0.40 NA; Carl Zeiss) magni-
fication using a charge-coupled device camera (Axiocam MRm; Carl Zeiss) 
at RT (22°C) and were acquired by AxioVision software (Carl Zeiss). 
Neurite analysis and measurements in cultured CGNs were performed   
using Neurolucida software (MBF Bioscience) in triplicate with 100 cells per 
triplicate. Neurite length was calculated as the mean neurite length per cell 
by measuring total neurite length and normalizing it to the number of cells 
included in the analysis (Tuj1-positive cells at 24 h).
RhoA activation assay
CGNs were plated on PDL and stimulated with 1 µM RA for 24 h. RhoA 
activity was determined from protein isolated from CGNs using the color-
meteric-based RhoA activation assay biochemistry kit (G-LISA; Cytoskele-
ton)  according  to  the  manufacturer’s  instructions.  In  brief,  protein  was 
isolated after 1 µg/ml MAG stress for 15 min using the provided cell lysis 
buffer, and cells were processed rapidly on ice and snap frozen until the 
time of assay. Lysates were clarified by centrifugation at 10,000 rpm at 
4°C for 2 min. Protein concentration was determined according to the 
manufacturer’s protocol, and cell extracts were equalized to contain pro-
tein concentrations of 0.41 µg/µl for the assay. RhoA activation was de-
tected with a spectrophotometer (Multiskan Ex; Thermo Fisher Scientific).
Overexpression and silencing experiments
Human RAR-2 (a gift from X.-C. Xu, University of Texas MD Anderson 
Cancer  Center,  Houston,  TX)  and  mouse  Lingo-1  (Origene)  expression 
constructs  were  transfected  into  CGNs  via  an  Amaxa  electroporation 
kit (Lonza) according to the manufacturer’s protocol. 3 µg plasmid with   
0.75 µg Amaxa EGFP was electroporated (G-013 program) into five to 
six million CGNs, which were then plated on either PDL or myelin with or 
without 1 µM RA stimulation for 24 h. The Amaxa EGFP plasmid was used 
as an electroporation control. For Lingo-1 gene silencing, a combination of 1155 RAR- promotes outgrowth by repressing Lingo-1 • Puttagunta et al.
inhibition in CGN. Fig. S2 further demonstrates that Lingo-1 overexpres-
sion counteracts RA-induced neurite outgrowth on myelin. Fig. S3 shows 
a significant decrease in both Lingo-1 gene and protein expression after   
24 h of Lingo-1 silencing in CGNs. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201102066/DC1.
We are grateful to Dr. Xiao-chun Xu for providing the human RAR-2 plasmid. 
We thank Bernd Knöll, Andrea Wizenmann, Ellen Batchelder, and Khizr Rathore 
for feedback regarding the manuscript. We also acknowledge Anja Wuttke 
for technical assistance in CGN extraction and myelin preparation and David 
Schöndorf for acquiring confocal images. Finally, we would like to thank   
Sergio Schinelli for his precious technical and conceptual contribution.
This work was supported by the Hertie Foundation and the National In-
stitutes of Health grants R21 NS052640 and DFG DI 1497/1-1 (all granted 
to S. Di Giovanni).
Submitted: 11 February 2011
Accepted: 25 May 2011
References
Agudo, M., P. Yip, M. Davies, E. Bradbury, P. Doherty, S. McMahon, M. Maden, 
and J.P. Corcoran. 2010. A retinoic acid receptor beta agonist (CD2019) 
overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase 
signalling in the injured adult spinal cord. Neurobiol. Dis. 37:147–155. 
doi:10.1016/j.nbd.2009.09.018
Barrette, B., N. Vallières, M. Dubé, and S. Lacroix. 2007. Expression profile of 
receptors for myelin-associated inhibitors of axonal regeneration in the 
intact and injured mouse central nervous system. Mol. Cell. Neurosci. 
34:519–538. doi:10.1016/j.mcn.2006.12.004
Bregman, B.S., E. Kunkel-Bagden, L. Schnell, H.N. Dai, D. Gao, and M.E. 
Schwab.  1995.  Recovery  from  spinal  cord  injury  mediated  by  anti-
bodies to neurite growth inhibitors. Nature. 378:498–501. doi:10.1038/ 
378498a0
Caroni, P., T. Savio, and M.E. Schwab. 1988. Central nervous system regen-
eration:  oligodendrocytes  and  myelin  as  non-permissive  substrates 
for neurite growth. Prog. Brain Res. 78:363–370. doi:10.1016/S0079- 
6123(08)60305-2
Chambon, P. 1996. A decade of molecular biology of retinoic acid receptors. 
FASEB J. 10:940–954.
Chapellier,  B.,  M.  Mark,  J.M.  Garnier,  M.  LeMeur,  P.  Chambon,  and  N.B. 
Ghyselinck.  2002.  A  conditional  floxed  (loxP-flanked)  allele  for  the 
retinoic  acid  receptor  alpha  (RARalpha)  gene.  Genesis.  32:87–90. 
doi:10.1002/gene.10071
Chen,  M.S.,  A.B.  Huber,  M.E.  van  der  Haar,  M.  Frank,  L.  Schnell,  A.A. 
Spillmann, F. Christ, and M.E. Schwab. 2000. Nogo-A is a myelin- 
associated neurite outgrowth inhibitor and an antigen for monoclonal   
antibody IN-1. Nature. 403:434–439. doi:10.1038/35000601
Corcoran,  J.,  P.L.  So,  R.D.  Barber,  K.J.  Vincent,  N.D.  Mazarakis,  K.A. 
Mitrophanous, S.M. Kingsman, and M. Maden. 2002. Retinoic acid re-
ceptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro. 
J. Cell Sci. 115:3779–3786. doi:10.1242/jcs.00046
Domeniconi, M., Z. Cao, T. Spencer, R. Sivasankaran, K. Wang, E. Nikulina, N. 
Kimura, H. Cai, K. Deng, Y. Gao, et al. 2002. Myelin-associated glyco-
protein interacts with the Nogo66 receptor to inhibit neurite outgrowth. 
Neuron. 35:283–290. doi:10.1016/S0896-6273(02)00770-5
Dubreuil, C.I., M.J. Winton, and L. McKerracher. 2003. Rho activation pat-
terns after spinal cord injury and the role of activated Rho in apopto-
sis  in  the  central  nervous  system.  J.  Cell  Biol.  162:233–243.  doi:10 
.1083/jcb.200301080
Encinas, M., M. Iglesias, N. Llecha, and J.X. Comella. 1999. Extracellular- 
regulated kinases and phosphatidylinositol 3-kinase are involved in brain- 
derived neurotrophic factor-mediated survival and neuritogenesis of the 
neuroblastoma cell line SH-SY5Y. J. Neurochem. 73:1409–1421. doi:10 
.1046/j.1471-4159.1999.0731409.x
Fournier, A.E., B.T. Takizawa, and S.M. Strittmatter. 2003. Rho kinase inhi-
bition enhances axonal regeneration in the injured CNS. J. Neurosci. 
23:1416–1423.
Gaub, P., A. Tedeschi, R. Puttagunta, T. Nguyen, A. Schmandke, and S. Di 
Giovanni. 2010. HDAC inhibition promotes neuronal outgrowth and coun-
teracts  growth  cone  collapse  through  CBP/p300  and  P/CAF-dependent   
p53 acetylation. Cell Death Differ. 17:1392–1408. doi:10.1038/cdd 
.2009.216
Glass, C.K., S.M. Lipkin, O.V. Devary, and M.G. Rosenfeld. 1989. Positive 
and  negative  regulation  of  gene  transcription  by  a  retinoic  acid- 
thyroid hormone receptor heterodimer. Cell. 59:697–708. doi:10.1016/ 
0092-8674(89)90016-0
Immunocytochemistry
Glass coverslips were coated with PDL at 0.1 mg/ml for 1 h at 37°C. For 
myelin experiments, these glass coverslips were additionally coated with   
4 µg/cm
2 myelin extracted from rat spinal cords for 2 h at 37°C (Gaub et al., 
2010). Cells were plated on coated coverslips with or without 1 µM RA 
(Sigma-Aldrich) for 24 h, at which time they were fixed with 4% parafor-
maldehyde/4% sucrose. For immunocytochemistry, cells were permeabi-
lized with 0.25% Triton X-100 in PBS for 5 min and then blocked with 1% 
BSA in PBS and 0.001% Tween. Cells were incubated overnight at 4°C 
with the primary antibody, mouse anti–III Tubulin (Promega). The follow-
ing day, cells were incubated for 30 min at RT with Alexa Fluor 568– 
phalloidin (Invitrogen) to visualize F-actin. After a brief rinse with PBS, the 
sections were incubated with FITC–Alexa Fluor 488 goat anti–mouse IgG 
secondary antibody (Thermo Fisher Scientific). To visualize each individual 
cell, we stained the nucleus with Hoechst 3325 (Invitrogen), rinsed the cells 
with PBS, and mounted them on slides with FluorSave (EMD). For Fig. 4 A, 
immunofluorescence (band pass 515/30 for FITC and band pass 590/60 
for Texas red) was detected using a confocal microscope (LSM 510, Axio-
vert 200M; Carl Zeiss), and pictures were taken at 20× (Plan-NEOFluar, 
0.50 NA) magnification at RT (22°C) and acquired by AIM software 
(Carl Zeiss).
Immunoblotting
For immunoblotting, cultured CGNs were collected at 24 h after plating 
and were lysed on ice for 30 min in a solution containing 10 mM Tris-HCl, 
1% Nonidet 40, 150 mM NaCl, 0.1% SDS, and 1% deoxycholate, pH 7.4, 
containing protease inhibitors (Complete Mini; Roche). The samples were 
then  processed  for  immunoblotting  as  previously  reported  (Gaub  et  al., 
2010)  according  to  standard  procedures.  Rabbit  polyclonal  Lingo-1 
(Millipore), mouse anti–-actin (Sigma-Aldrich), and mouse anti–glyceral-
dehyde-3-phosphate dehydrogenase (Millipore) were used as primary 
antibodies. Quantitation of protein expression was performed by densi-
tometry (Photoshop; Adobe) of the representative bands of the immuno-
blots and normalized to the respective levels of -actin.
Quantitative real-time RT-PCR analysis
RNA was extracted from CGNs using TRIZOL reagent (Invitrogen), and 
cDNA was synthesized from 0.5 µg of total RNA using both oligo(dT) 
and random hexamers from the SuperScript II Reverse Transcription kit 
(Invitrogen). Quantities and fold changes were calculated according to 
the Ct method in three independent experiments performed in triplicate 
according to the manufacturer’s instructions (ABI 7000) and as previously 
reported (Tedeschi et al., 2009a,b). For real-time RT-PCR, the primers used 
were Lingo-1 forward 5-GCCTCAACCTGACATCCCTA-3 and reverse 
5-TTGCCAGAGACATTGAGCAC-3 (250 bp); NogoR1 forward 5-CTG-
GAGGGTAGCAACACCAT-3 and reverse 5-TGCAGCCACAGGATAGT-
GAG-3 (207 bp); TROY forward 5-ATTCCCTCAATCCCGAAAAC-3  
and reverse 5-GTCCTTTGAGCATCCTGAGC-3 (178 bp); p75
NTR forward   
5-CCCAGAATAGCAACCAGGAA-3 and reverse 5-ATCGGAAGTTAG-
GGGCAAGT-3 (217 bp); and RPL13A forward 5-CCCTCCACCCTAT-
GACAAGA-3 and reverse 5-CCTTTTCCTTCCGTTTCTCC-3 (167 bp). 
RPL13A was used for normalization.
SCI
This study was performed in accordance with the Animal Care and Use 
Committee of the University of Tuebingen. Surgeries were performed on 
adult wild-type and RAR-
/ (Chapellier et al., 2002) mice. A dorsal col-
umn overhemisection lesion of the spinal column was performed at thoracic 
level T8 using a precision steel blade, severing the dorsal columns and the 
corticospinal tracts. Starting on the injury day, the animals were treated with 
5 mg/kg RA or vehicle (DMSO) via IP injection for a consecutive 14 d. 2 wk 
after injury, the animals were sacrificed to collect the 1-cm SCI site to be 
processed for immunoblotting analysis of Lingo-1 expression. Three ani-
mals per group per genotype were used: laminectomy (Sham), dorsal col-
umn lesion treated with vehicle (SCI control), or RA (SCI RA).
Statistical analysis
Data are plotted as the mean ± SEM. All experiments were performed in 
triplicate. Asterisks indicate a significant difference analyzed by a one-way 
analysis of variance (ANOVA) with Bonferroni posttests or an unpaired two-
tailed t test as indicated (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Online supplemental material
Fig. S1 shows that RA does not affect CGN survival. It also shows that 
RA induces RAR- expression on myelin, an induction not observed in 
RAR-
/ CGN. Finally, Fig. S1 shows that RA does not overcome CSPG JCB • VOLUME 193 • NUMBER 7 • 2011   1156
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